DOCSLIB.ORG

Benfluorex: What Use? a SECOND LOOK POOR ASSESSMENT FILE

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Benfluorex: What Use? a SECOND LOOK POOR ASSESSMENT FILE New products necessitating blood transfusions 3- “Paclitaxel” Prescr Intern 1994; 3 (14): 164-165. Literature 4- Rowisky EK et al. “Phase I and pharmacolog- occurred in 37% of patients (9). ic study of topotecan: a novel topoisomerase I The most frequent non haematologi- Our literature search was based on systematic inhibitor” J Clin Oncol 1992; 10: 647-656. cal side effects were nausea (68.1% of scrutiny of contents listings of the main inter- 5- Verweij L et al. “Phase I and pharmacokinet- ics study of topotecan, a new topoisomerase I patients, severe in 6.1% of patients), national journals and Current Contents at inhibitor” Ann Oncol 1993; 4: 673-678. vomiting (44.3%, severe in 4.5%), hair the Prescrire library, and on reference texts 6- Saltz L et al. “Phase I clinical and pharmacol- in clinical pharmacology (Martindale The ogy study of topotecan given daily for 5 consecu- loss (56.9%), fatigue (44.5%, severe in Extra Pharmacopoeia 31st ed., etc.). We also tive days to patients with advanced solid tumors, 6%), diarrhoea (26.1%, severe in 3.4%), consulted CD-ROM versions of Medline (1981- with attempt at dose intensification using recom- and stomatitis (20.2%, severe in 2%) (9). March 1998), Embase Drugs and binant granulocyte colony-stimulating factor” J Pharmacology (1991-January 1998), Cochrane Natl Cancer Inst 1993; 85 (18): 1499-1507. Paclitaxel solution contains a solvent, 7- Kudelka AP et al. “Phase II study of intravenous Cremophor EL°, that is incompatible with (1998, issue 1), Medidoc (1991-1994) and topotecan as a 5-day infusion for refractory epithe- Reactions (1983-June 1997), and the Minitel lial ovarian carcinoma” J Clin Oncol 1996; 14: the use of PVC infusion devices and war- version of the Pascal database up to 1552-1557. rants prior steroid administration because September 16 1997. SmithKline Beecham 8- Creemers GJ et al. “Topotecan, an active drug of its high sensitising potential (3). This is provided us with published and unpublished in the second-line treatment of epithelial ovarian documents, including the clinical expert cancer: results of a large European phase II study” not the case with topotecan. J Clin Oncol 1996; 14: 3056-3061. report. We also used the European public In all, 0.9% of patients died from 9- Ten Bokkel Huinink et al. “Topotecan versus assessment report (EPAR) available from the proven or probable toxicity on topote- paclitaxel for the treatment of recurrent epithelial European medicines agency. ovarian cancer” J Clin Oncol 1997; 15: 2183-2193. can, an incidence similar to that report- 10- European Agency for Medicinal Products ed with paclitaxel (9,11). And 5% of 1- NIH Consensus Development Panel on Ovarian (EMEA) “European public assessment report Cancer “Ovarian cancer - Screening, treatment (EPAR) Hycamtin” November 12, 1996: 32 pages. patients discontinued treatment with and follow-up” JAMA 1995; 273: 491-497. 11- Trimble EL et al. “Paclitaxel for platinum-refrac- topotecan because of severe adverse 2- Van Der Burg MEL et al. “The effect of debulk- tory ovarian cancer: results from the first 1 000 events (9). ing surgery after induction chemotherapy on the patients registered to National Cancer Institute prognosis in advanced epithelial ovarian cancer” Treatment Referral Center 9103” J Clin Oncol ©PI N Engl J Med 1995; 332: 629-634. 1993; 11: 2405-2410. Translated from Rev Prescr Dec 1997; 17 (179): 807-809 benfluorex: what use? A SECOND LOOK POOR ASSESSMENT FILE Abstract been done with morbidity or mortality contradictory. None of the three trials as end points. Available placebo-con- comparing benfluorex with a fibrate is ● The clinical file on the value of ben- trolled trials are small, methodologi- interpretable, because of fluorex for hypertriglyceridaemia is cally weak in most cases, and their methodological problems. highly inadequate. No clinical trials have results regarding triglyceride levels are NOTHING There is no reason to prescribe benfluorex for hypertriglyceridaemia and diabetes. NEW enfluorex (Biopharma, Servier most important question is the following: Tablets group), has been marketed in does benfluorex have proven • 150 mg per tablet B France since 1976, as tablets con- taining 150 mg (a). Chemically, benfluo- Biopharma a-In Europe, benfluorex is also marketed in Spain, rex is similar to other appetite suppres- Greece, Italy, Luxemburg, Portugal and ■ licensed indication in lipid disor- sants (b)(1). In France benfluorex has Switzerland (1). Benfluorex is not marketed in ders two approved indications. We recently English-speaking countries or Northern Europe. b- In France benfluorex has a peculiar classifica- “Adjunct to appropriate dietary mea- took another look at the file on the indi- tion. It is not officially classified among the appetite sures in hypertriglyceridaemia. The cation worded “adjunct to dietary mea- suppressants, meaning that its prescription is not restricted. However, the authorities decided on dietary measures must be continued. sures in asymptomatic overweight dia- October 25, 1995 (Journal Officiel, October 31, NB. There is no proven efficacy in pri- betic patients”, and concluded that its 1995: 15 937) to place benfluorex on a list of sub- mary or secondary prevention of com- stances that must not be used in freshly prepared slight effects on surrogate end points in mixtures, a list composed only of appetite sup- plications of atherosclerosis.” no way warranted prescription to diabetic pressants. Furthermore, the suffix -orex is attrib- uted to international nonproprietary names of lipid-lowering drug? patients (2). appetite suppressants by the World Health The second approved indication for Organisation (WHO) (1), and benfluorex is on the list of doping substances, together with amphetamines benfluorex is in the treatment of hyper- and other stimulants (Dictionnaire Vidal, French triglyceridaemia (see inset opposite). The data sheet compendium, 1997 edition, page 6). P RESCRIRE I NTERNATIONAL A PRIL 1998/VOLUME 7 N° 34 • 49 Downloaded from english.prescrire.org on 28/09/2021 Copyright(c)Prescrire. For personal use only. New products / benfluorex ᮣ beneficial effects on the only clinical- treatment, five trials showed a statisti- f- The report does not state whether the investi- ly relevant end point, i.e. cardiovascular cally significant difference in triglyceride gators or the patients were blinded. g- The patients weighed at least 65 kg, in which morbidity and mortality, in patients with or levels between benfluorex and the place- case the recommended dose of clofibrate is without a history of cardiovascular dis- bo, while five showed no such difference. 2 g/day. ease? h- The authors themselves stated that the prob- Trials versus other lipid-lowering ability of a response to pharmacological treatment A consensus conference in the United drugs: uninterpretable results. Three was higher in the case of type IV dyslipidaemia States was devoted to hypertriglyceri- trials comparing benfluorex with other than in type IIB dyslipidaemia. daemia (3). According to the conclusions, lipid-lowering drugs have been published only marked hypertriglyceridaemia war- in detail (12-14). Two of these trials com- rants treatment, with the aim not only of pared benfluorex with clofibrate in reducing the hypertriglyceridaemia, but patients with hypertriglyceridaemia (at Literature more importantly of reducing LDL-cho- least 1.5 g/l) and/or hypercholestero- lesterol levels and increasing HDL-cho- Our literature search was based on system- laemia (cholesterol level above atic scrutiny of contents listings of the main lesterol levels. This is because the link 2.5 g/l) (e). The first trial was single-blind international journals and Current Contents between cholesterol fractions and car- and involved 40 patients (f)(12). While at the Prescrire library, and on reference diovascular morbidity is better estab- total triglyceride levels fell more strong- texts in clinical pharmacology (Martindale lished than for triglycerides. First-line ly on benfluorex (52.7% versus 38.5% The Extra Pharmacopoeia, etc.). We also management of hypertriglyceridaemia is consulted CD-ROM versions of Medline on average; p<0.001), the result was (1966-January 1998), Embase Drugs and based on lifestyle measures (giving up meaningless for at least two reasons: Pharmacology (1991-December 1997), smoking and alcohol, taking exercise, firstly, 15 of the 20 patients received only Reactions (1983, December 1997), and etc.) and dietary advice (increasing oily 1.5 g of clofibrate daily, an inadequate Cochrane (1998, issue 1), and the Minitel fish consumption). According to the version of the Pascal and EMC databases, up dose (g); secondly, patient recruitment to October 18, 1997. Servier sent us pub- American consensus conference, drugs was highly heterogeneous, the clofibrate lished and unpublished documents. Two are useful only when these measures group comprising more patients with type ISDB members (International Society of are inadequate (3). IIb hyperlipidaemia and fewer patients Drug Bulletins) - Boletin Terapeutico Lipid-lowering drugs known to induce Andaluz and Informazion sui Farmaci - sent with type IV hyperlipidaemia than the us their documentation. a marked reduction in hypertriglyceri- benfluorex group (h). daemia are the fibrates, nicotinic acid The second trial, involving 28 patients, 1- “Benfluorex°” Micromedex 31/03/1996; 87: 9 and fish oils (c)(3,4). Gemfibrozil, a pages. is also uninterpretable: blinding was not 2- “Benfluorex antidiabetic?” Prescr Intern 1997; 6 fibrate, is the only drug having shown a mentioned and this leads us to believe (30): 108-109. preventive action, based on clinical cri- that it was not done; the daily dose of 3- NIH consensus development panel on triglyc- teria, in a trial involving patients with eride, high-density lipoprotein, and coronary heart clofibrate was probably inadequate for a disease “Triglyceride, high-density lipoprotein, and hypertriglyceridaemia (d)(3,5). number of patients; and the distribution coronary heart disease” JAMA 1993; 269 (4): 505- We examined the clinical file on ben- of the various types of dyslipidemia was 510. fluorex for answers to the following ques- 4- “Lipid regulating agents”.
Load more

Recommended publications
  • Obesity Drugs: Too Much Harm, for Far Too Long
    Obesity drugs: too much harm, for far too long In 2016, a British team studied the causes for the market withdrawals of weight-loss drugs. They identified 25 drugs that had been withdrawn from markets around the world between 1964 and 2009. The mechanism of 22 of these drugs involved monoamine neurotransmitters (dopamine, noradrenaline or serotonin); examples include benfluorex, fenfluramine, phentermine (combined with topiramate in the United States) and sibutramine. One drug, rimonabant, was a cannabinoid EDITORIAL derivative, and the two others acted on the thyroid (1). 80% of the market withdrawals were based on data from spontaneous reports, involving cardiac disorders for 8 drugs, psychiatric disorders for 7 drugs, and abuse or dependence for 13 drugs. Drug-attributed deaths had occurred with 7 of the drugs. The median time between market introduction and the first report of a serious adverse effect was 10 years; and the median time between the first report of a serious adverse effect and the first market withdrawal anywhere in the world was 11 years. Fenfluramine was marketed for 24 years before its worldwide withdrawal in 1997 for heart valve disease. Benfluorex was marketed in France for 33 years before its withdrawal in 2009 for cardiotoxicity; yet the heart valve disorders resembled those caused by fenfluramine and the chemical structures of these two drugs are very similar (2). In France, phentermine was marketed from 1962 to 1988. Sibutramine was withdrawn in Europe in 2010, about 9 years after authorisation; and rimonabant was withdrawn in Europe in 2009, about 2 years after authorisation (1,3,4).
    [Show full text]
  • Pharmaceuticals Appendix
    )&f1y3X PHARMACEUTICAL APPENDIX TO THE HARMONIZED TARIFF SCHEDULE )&f1y3X PHARMACEUTICAL APPENDIX TO THE TARIFF SCHEDULE 3 Table 1. This table enumerates products described by International Non-proprietary Names (INN) which shall be entered free of duty under general note 13 to the tariff schedule. The Chemical Abstracts Service (CAS) registry numbers also set forth in this table are included to assist in the identification of the products concerned. For purposes of the tariff schedule, any references to a product enumerated in this table includes such product by whatever name known. Product CAS No. Product CAS No. ABAMECTIN 65195-55-3 ADAPALENE 106685-40-9 ABANOQUIL 90402-40-7 ADAPROLOL 101479-70-3 ABECARNIL 111841-85-1 ADEMETIONINE 17176-17-9 ABLUKAST 96566-25-5 ADENOSINE PHOSPHATE 61-19-8 ABUNIDAZOLE 91017-58-2 ADIBENDAN 100510-33-6 ACADESINE 2627-69-2 ADICILLIN 525-94-0 ACAMPROSATE 77337-76-9 ADIMOLOL 78459-19-5 ACAPRAZINE 55485-20-6 ADINAZOLAM 37115-32-5 ACARBOSE 56180-94-0 ADIPHENINE 64-95-9 ACEBROCHOL 514-50-1 ADIPIODONE 606-17-7 ACEBURIC ACID 26976-72-7 ADITEREN 56066-19-4 ACEBUTOLOL 37517-30-9 ADITOPRIME 56066-63-8 ACECAINIDE 32795-44-1 ADOSOPINE 88124-26-9 ACECARBROMAL 77-66-7 ADOZELESIN 110314-48-2 ACECLIDINE 827-61-2 ADRAFINIL 63547-13-7 ACECLOFENAC 89796-99-6 ADRENALONE 99-45-6 ACEDAPSONE 77-46-3 AFALANINE 2901-75-9 ACEDIASULFONE SODIUM 127-60-6 AFLOQUALONE 56287-74-2 ACEDOBEN 556-08-1 AFUROLOL 65776-67-2 ACEFLURANOL 80595-73-9 AGANODINE 86696-87-9 ACEFURTIAMINE 10072-48-7 AKLOMIDE 3011-89-0 ACEFYLLINE CLOFIBROL 70788-27-1
    [Show full text]
  • The Curtailment of the European Medicines Agency’S Policy on Access to Documents
    Supplementary Online Content Doshi P. Transparency interrupted: the curtailment of the European Medicines Agency’s policy on access to documents. JAMA Intern Med. Published online August 19, 2013. doi:10.1001/jamainternmed.2013.9989 eAppendix. Table of European Medicines Agency Freedom of Information Requests Snapshot Dated June 4, 2013 This supplementary material has been provided by the authors to give readers additional information about their work. © 2013 American Medical Association. All rights reserved. Downloaded From: https://jamanetwork.com/ on 10/02/2021 Category of documents Category of documents Affiliation according to Closed Product / subject Pages requested requested social and occupational Received Pending Replied released DOSSIER NON-DOSSIER profile Open Mixed documents Academia/Research Avandia (rosiglitazone) institute 14/12/10 Closed 13/01/11 1,048 Somatropin Studies Other 13/12/10 Closed 14/01/11 0 Tasocitinib Dossier, SA Legal 16/12/10 Closed 18/01/11 0 Duloxetines: Module 5 Ariclaim; Cymbalta; Xeristar; Yentreve Healthcare professional 15/12/10 Closed 16/05/11 13,731 Infanrix HepB Mixed documents Legal 16/12/10 Closed 16/02/11 247 AR, minutes, Dossier, CSR Avonex (interferon beta-1a) Healthcare professional 30/11/10 Closed 04/02/11 18 Travatan (travoprost) AR, PSUR Media 21/12/10 Closed 21/01/11 474 PhVWP H1N1 (pandemic influenza vaccine) EU Institution (EC etc) 20/10/10 Closed 08/02/11 42 Plavix (clopidogrel) CSR Media 04/01/11 Closed 06/09/12 70,291 Referral documents Agreal (veralipride) Patients organisation
    [Show full text]
  • 2012 Harmonized Tariff Schedule Pharmaceuticals Appendix
    Harmonized Tariff Schedule of the United States (2014) (Rev. 1) Annotated for Statistical Reporting Purposes PHARMACEUTICAL APPENDIX TO THE HARMONIZED TARIFF SCHEDULE Harmonized Tariff Schedule of the United States (2014) (Rev. 1) Annotated for Statistical Reporting Purposes PHARMACEUTICAL APPENDIX TO THE TARIFF SCHEDULE 2 Table 1. This table enumerates products described by International Non-proprietary Names (INN) which shall be entered free of duty under general note 13 to the tariff schedule. The Chemical Abstracts Service (CAS) registry numbers also set forth in this table are included to assist in the identification of the products concerned. For purposes of the tariff schedule, any references to a product enumerated in this table includes such product by whatever name known. ABACAVIR 136470-78-5 ACEVALTRATE 25161-41-5 ABAFUNGIN 129639-79-8 ACEXAMIC ACID 57-08-9 ABAGOVOMAB 792921-10-9 ACICLOVIR 59277-89-3 ABAMECTIN 65195-55-3 ACIFRAN 72420-38-3 ABANOQUIL 90402-40-7 ACIPIMOX 51037-30-0 ABAPERIDONE 183849-43-6 ACITAZANOLAST 114607-46-4 ABARELIX 183552-38-7 ACITEMATE 101197-99-3 ABATACEPT 332348-12-6 ACITRETIN 55079-83-9 ABCIXIMAB 143653-53-6 ACIVICIN 42228-92-2 ABECARNIL 111841-85-1 ACLANTATE 39633-62-0 ABETIMUS 167362-48-3 ACLARUBICIN 57576-44-0 ABIRATERONE 154229-19-3 ACLATONIUM NAPADISILATE 55077-30-0 ABITESARTAN 137882-98-5 ACLIDINIUM BROMIDE 320345-99-1 ABLUKAST 96566-25-5 ACODAZOLE 79152-85-5 ABRINEURIN 178535-93-8 ACOLBIFENE 182167-02-8 ABUNIDAZOLE 91017-58-2 ACONIAZIDE 13410-86-1 ACADESINE 2627-69-2 ACOTIAMIDE 185106-16-5
    [Show full text]
  • Government Gazette
    Government Gazette REPUBLIC OF SOUTH AFRICA Regulation Gazette No. 7636 Vol. 454 Pretoria 10 April 2003 No. 24727 AIDS HELPLINE: 0800-0123-22 Prevention is the cure I STAATSKOERANT, 10 APRIL 2003 No. 24727 3 GOVERNMENT NOTICES GOEWERMENTSKENNISGEWINGS DEPARTMENT OF HEALTH DEPARTEMENT VAN GESONDHEID NO. R. 509 10 April 2003 SCHEDULES The Minister of Health has, in terms of section 22A(2) of the Medicines and Related Substances Act, 1965 (Act No. 101 of 1965), on the recommendation of the Medicines Control Council, made the Schedulesin the Schedule SCHEDULE I In these Schedules, "the Act" meansthe Medicines and Related SubstancesAct, 1965 (Act No. 101 of 1965) SCHEDULE 0 (a) All substancesreferred to in thisSchedule are excluded when specifically packed, labelled and usedfor - (i) industrialpurposes including the manufacture or compounding of consumer items or products which have no pharmacological oraction medicinal purpose, which are intended to be ingested by man or animals as food, or applied to the body as a cosmetic, and which are approved for such use in terms of the Foodstuffs, Cosmetics and Disinfectants Act, 1972 (Act No. 54 of 1972) or registeredin terms of theFertilizers, Farm Feeds, Agricultural Remedies and Stock Remedies Act, 1947 (Act No. 36 of 1947); and (ii)analytical laboratory purposes. (b) All substances referred to in this Schedule include the following: 4 No. 24727 GOVERNMENT GAZETTE, 10 APRIL 2003 (i) The saltsand esters of suchsub2ances,+vhere the existence of such salts and esters is possible; and (ii) All preparationsand mixtures of suchsubstances where such preparations and mixtures arenot expressly excluded. This Schedule includesall substances subject to registration in termsof the Act and which are not listed in anyof the other Schedules.
    [Show full text]
  • Marrakesh Agreement Establishing the World Trade Organization
    No. 31874 Multilateral Marrakesh Agreement establishing the World Trade Organ ization (with final act, annexes and protocol). Concluded at Marrakesh on 15 April 1994 Authentic texts: English, French and Spanish. Registered by the Director-General of the World Trade Organization, acting on behalf of the Parties, on 1 June 1995. Multilat ral Accord de Marrakech instituant l©Organisation mondiale du commerce (avec acte final, annexes et protocole). Conclu Marrakech le 15 avril 1994 Textes authentiques : anglais, français et espagnol. Enregistré par le Directeur général de l'Organisation mondiale du com merce, agissant au nom des Parties, le 1er juin 1995. Vol. 1867, 1-31874 4_________United Nations — Treaty Series • Nations Unies — Recueil des Traités 1995 Table of contents Table des matières Indice [Volume 1867] FINAL ACT EMBODYING THE RESULTS OF THE URUGUAY ROUND OF MULTILATERAL TRADE NEGOTIATIONS ACTE FINAL REPRENANT LES RESULTATS DES NEGOCIATIONS COMMERCIALES MULTILATERALES DU CYCLE D©URUGUAY ACTA FINAL EN QUE SE INCORPOR N LOS RESULTADOS DE LA RONDA URUGUAY DE NEGOCIACIONES COMERCIALES MULTILATERALES SIGNATURES - SIGNATURES - FIRMAS MINISTERIAL DECISIONS, DECLARATIONS AND UNDERSTANDING DECISIONS, DECLARATIONS ET MEMORANDUM D©ACCORD MINISTERIELS DECISIONES, DECLARACIONES Y ENTEND MIENTO MINISTERIALES MARRAKESH AGREEMENT ESTABLISHING THE WORLD TRADE ORGANIZATION ACCORD DE MARRAKECH INSTITUANT L©ORGANISATION MONDIALE DU COMMERCE ACUERDO DE MARRAKECH POR EL QUE SE ESTABLECE LA ORGANIZACI N MUND1AL DEL COMERCIO ANNEX 1 ANNEXE 1 ANEXO 1 ANNEX
    [Show full text]
  • List Item Benfluorex
    ANNEX I LIST OF THE INVENTED NAMES, PHARMACEUTICAL FORMS, STRENGTH OF THE MEDICINAL PRODUCTS, ROUTE OF ADMINISTRATION AND MARKETING AUTHORISATION HOLDERS IN THE MEMBER STATES (EEA) 1 Member State Pharmaceutical Marketing Authorisation Holder Invented Name Strength Route of administration (EEA) Form Les Laboratoires Servier 22, rue Garnier Lipophoral CY - Cyprus 150mg tablet oral F- 92200 Neuilly-sur-Seine Tablets 150mg France Les laboratoires Servier 22 rue Garnier FR - France Mediator 150 mg tablet oral F-92200 Neuilly-sur-Seine France Mylan SAS 117 allée des Parcs FR - France Benfluorex Mylan 150 mg tablet oral 69800 Saint-Priest France Qualimed 117 allée des Parcs Benfluorex FR - France 150 mg tablet oral 69800 Saint-Priest Qualimed France Les Laboratoires Servier 22, rue Garnier LU - Luxembourg Mediator 150mg tablet oral F- 92200 Neuilly-sur-Seine France Servier Portugal - Especialidades Farmacêuticas, Lda. PT - Portugal Av. António Augusto de Aguiar Mediator 150 mg coated tablet oral 128, 1069-133 Lisboa Portugal 2 ANNEX II SCIENTIFIC CONCLUSIONS AND GROUNDS FOR THE REVOCATION OF THE MARKETING AUTHORISATIONS PRESENTED BY THE EUROPEAN MEDICINES AGENCY 3 SCIENTIFIC CONCLUSIONS OVERALL SUMMARY OF THE SCIENTIFIC EVALUATION OF MEDICINAL PRODUCTS CONTAINING BENFLUOREX (see Annex I) Benfluorex is used as an adjunct in the management of type 2 diabetes mellitus in overweight patients. The currently authorised therapeutic indication in France is as « Adjuvant therapy of overweight diabetics, in combination with an appropriate diet». Benfluorex has an action on carbohydrate metabolism. In animals, the following effects have been observed: - Facilitation of precipitation and use of glucose in cells (rats); - Reduction in hyperglycaemia in diabetic rats (insulin deprived or not), decrease in hyperglycaemia (measured by the glucose tolerance test area) in rabbits.
    [Show full text]
  • Efficacy of Benfluorex in Combination with Sulfonylurea in Type 2
    Clinical Care/Education/Nutrition ORIGINAL ARTICLE Efficacy of Benfluorex in Combination With Sulfonylurea in Type 2 Diabetic Patients An 18-week, randomized, double-blind study 1 6 PHILIPPE MOULIN, MD, PHD DRAGOMIR KOEV, MD apy is being recognized as desirable in 2 7 MARIE ANDRE, MD RAY MOORE, MRCP type 2 diabetes. According to the patho- 3 8 HASAN ALAWI, MD VIOREL SERBAN, MD 4 2 physiological mechanism of the disease, LELITA C. DOS SANTOS, MD BRIGITTE PICANDET, MD 5 2 the combination of an insulin secreta- ABDUL K. KHALID, MD MARIE FRANCILLARD, MD, PHD gogue with an insulin sensitizer is the most common drug treatment proposed for type 2 diabetic patients, in addition to OBJECTIVE — The aim of this study was to demonstrate the superiority of benfluorex over diet, lifestyle counseling, and exercise. In- placebo as an add-on therapy in type 2 diabetic patients in whom diabetes is insufficiently sulin sensitizers are not a homogenous controlled by sulfonylurea monotherapy and who have a limitation for the use of metformin. drug class. For many years, metformin was the only drug of this type on the RESEARCH DESIGN AND METHODS — Type 2 diabetic patients with HbA1c (A1C) (7–10%) who were receiving the maximum tolerated sulfonylurea dose and had a contraindi- market; now thiazolidinediones are an cation to or poor tolerance of metformin were randomly assigned (double blind) to receive alternative. Both metformin and thiazo- benfluorex 450 mg/day (n ϭ 165) or placebo (n ϭ 160) for 18 weeks. The main efficacy criterion lidinediones have limitations on their use: was A1C, analyzed as the change from baseline to the end of treatment using ANCOVA with gastrointestinal intolerance is common with baseline and country as covariates.
    [Show full text]
  • Impending Approval of a Dangerous Amphetamine Drug for Use in Weight Control? an Unacceptable EMA Recommendation That Must Be Overturned
    Impending approval of a dangerous amphetamine drug for use in weight control? An unacceptable EMA recommendation that must be overturned PRESS RELEASE – Paris, 19 December 2014. Today, the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has announced its decision to recommend that marketing authorisation be granted for the combination naltrexone + amfebutamone (also known as bupropion) for use in weight control (MYSIMBA° in the EU/CONTRAVE° in other parts of the world), despite “uncertainties with regard to cardiovascular outcomes in the longer term” (1). A major regression for European patients’ safety. Amfebutamone is an amphetamine drug, as is amfepramone. In 2000, the EMA withdrew the marketing authorisation of several appetite suppressants with a similar mechanism of action to that of amfepramone (clobenzorex, dexfenfluramine, fenfluramine, fenproporex, etc.), in order to protect public health (2). In 2009, sibutramine (Sibutral°), an appetite suppressant structurally related to amphetamines, was also withdrawn by the EMA due to disproportionate and serious adverse drug reactions (3). And benfluorex (Mediator°) was also withdrawn from the whole European Union market in 2010 (4). In addition, in 2013, the EMA rightly refused to authorise the dangerous fixed-dose combination phentermine + topiramate on safety grounds, and the application for the drug lorcaserin (Belviq°) was withdrawn by the company following the CHMP’s “provisional opinion that Belviq could not have been approved for weight control in obese and overweight patients” (5,6). How is it possible that the CHMP now takes an incongruent decision on the fixed-dose weight-control combination naltrexone + amfebutamone (also known as bupropion) (CONTRAVE°/MYSIMBA°)? Health authorities should learn from past public health disasters.
    [Show full text]
  • Federal Register / Vol. 60, No. 80 / Wednesday, April 26, 1995 / Notices DIX to the HTSUS—Continued
    20558 Federal Register / Vol. 60, No. 80 / Wednesday, April 26, 1995 / Notices DEPARMENT OF THE TREASURY Services, U.S. Customs Service, 1301 TABLE 1.ÐPHARMACEUTICAL APPEN- Constitution Avenue NW, Washington, DIX TO THE HTSUSÐContinued Customs Service D.C. 20229 at (202) 927±1060. CAS No. Pharmaceutical [T.D. 95±33] Dated: April 14, 1995. 52±78±8 ..................... NORETHANDROLONE. A. W. Tennant, 52±86±8 ..................... HALOPERIDOL. Pharmaceutical Tables 1 and 3 of the Director, Office of Laboratories and Scientific 52±88±0 ..................... ATROPINE METHONITRATE. HTSUS 52±90±4 ..................... CYSTEINE. Services. 53±03±2 ..................... PREDNISONE. 53±06±5 ..................... CORTISONE. AGENCY: Customs Service, Department TABLE 1.ÐPHARMACEUTICAL 53±10±1 ..................... HYDROXYDIONE SODIUM SUCCI- of the Treasury. NATE. APPENDIX TO THE HTSUS 53±16±7 ..................... ESTRONE. ACTION: Listing of the products found in 53±18±9 ..................... BIETASERPINE. Table 1 and Table 3 of the CAS No. Pharmaceutical 53±19±0 ..................... MITOTANE. 53±31±6 ..................... MEDIBAZINE. Pharmaceutical Appendix to the N/A ............................. ACTAGARDIN. 53±33±8 ..................... PARAMETHASONE. Harmonized Tariff Schedule of the N/A ............................. ARDACIN. 53±34±9 ..................... FLUPREDNISOLONE. N/A ............................. BICIROMAB. 53±39±4 ..................... OXANDROLONE. United States of America in Chemical N/A ............................. CELUCLORAL. 53±43±0
    [Show full text]
  • Synthese MEDIATOR
    Inspection générale des affaires sociales RM2011-001P Enquête sur le MEDIATOR ® SYNTHESE Dr. Anne-Carole Bensadon, Etienne Marie et Dr.Aquilino Morelle Membres de l’Inspection générale des affaires sociales - Janvier 2011 - Synthèse du rapport [1] Le ministre du travail, de l’emploi et de la santé a saisi le 29 novembre 2010 l’Inspection générale des affaires sociales d’une mission d’enquête relative au Médiator. A l’issue de ses six semaines de travail, de la centaine d’auditions qu’elle a menée et de l’exploitation des dossiers scientifiques et administratifs s’échelonnant sur 40 années, la mission est en mesure de reconstituer la succession des événements et des choix qui sont allés de l’autorisation en 1974 au retrait en 2010 du médicament. Son rapport s’appuie sur près de 200 annexes pour assurer la plus grande transparence au débat public à venir. [2] Le rapport est organisé à la fois autour des principaux temps de la vie du médicament et autour de l’analyse des principales responsabilités identifiées par la mission : • les laboratoires Servier qui dès l’origine du médicament ont poursuivi un positionnement du MEDIATOR ® en décalage avec sa réalité pharmacologique (1) ; • l’Agence chargée du médicament, inexplicablement tolérante à l’égard d’un médicament sans efficacité thérapeutique réelle (2) ; • le système de pharmacovigilance, incapable d’analyser les graves risques apparus en termes de cardiotoxicité du MEDIATOR ® (3) ; • enfin, les ministres chargés de la sécurité sociale et de la santé gérant avec lenteur les déremboursements de médicaments à service médical rendu insuffisant, aboutissant dans le cas du MEDIATOR ® à des résultats inverses de ceux recherchés (4).
    [Show full text]
  • Médiator® (Chlorhydrate De Benfluorex)
    Propriétés Pharmacologiques du benfluorex Dr Philippe LECHAT Professeur des Universités, Praticien hospitalier Directeur de l’évaluation des médicaments et des produits biologiques - Afssaps Plan du document - Introduction - Historique du développement des anorexigènes - Pharmacologie comparée des fenfluramines et des amphétamines o Amphétamine o Fenfluramines - Données pharmacocinétiques de la fenfluramine - Données pharmacocinétiques de la d-fenfluramine - Rôle des métabolites dans l’action pharmacologique des fenfluramines - Pharmacologie du benfluorex o Données pharmacocinétiques du benfluorex o Mécanismes des actions périphériques pulmonaires et cardiaques des fenfluramines - Récepteurs sérotoninergiques et hypertension artérielle pulmonaire - Récepteurs sérotoninergiques et valvulopathies - Actions métaboliques périphériques du benfluorex - - Conclusions - - Annexes : o 1 - Bibliographie générale o 2 - Bibliographie sur le métabolisme périphérique du benfluorex o 3 - Données pharmacocinétiques comparatives chez le sujet sain entre fenfluramine, d-fenfluramine et benfluorex o 4 - Métabolisme du benfluorex o 5 - Nombre de traitements annuels de benfluorex (données Servier) o 6 - Formules chimiques des différents anorexigènes Afssaps – 31 décembre 2010 1/33 Introduction Le benfluorex a été commercialisé en France de 1976 à 2009 sous le nom de Médiator après avoir obtenu son AMM en France en 1974. Il appartient à la famille des fenfluramines dont les principaux autres représentants ont été : La dl fenfluramine (Pondéral), avec une AMM française obtenue en 1965 et l’isomère d, la d-fenfluramine ou dex-fenfluramine (Isoméride) qui a obtenu son AMM en France en 1985. Isoméride et Pondéral ont été retirés du marché en 1997 suite à la mise en évidence d’effets indésirables graves à type de valvulopathies cardiaques et d’hypertension artérielle pulmonaire. Ces deux médicaments avaient les indications des médicaments de la classe des anorexigènes.
    [Show full text]